Online inquiry

IVTScrip™ mRNA-Anti-alpha toxin&lukE, ASN-1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3281MR)

This product GTTS-WQ3281MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets alpha toxin&
lukE gene. The antibody can be applied in Staphylococcal infections research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq WP_000473596.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2828033; 59700577
UniProt ID P09616; A0A0H2WWN3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-alpha toxin&lukE, ASN-1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3281MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2968MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ANB020
GTTS-WQ14526MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SA-237
GTTS-WQ4961MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA c2G4-N
GTTS-WQ7865MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ6212MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CR4098
GTTS-WQ5237MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CB 2679d
GTTS-WQ3383MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AT-005
GTTS-WQ6348MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CSL-362-AML
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW